With the tightening of supervision in the pharmaceutical industry, cases of pharmaceutical companies being punished have been occurring
from time to time.
It is reported that recently, many local drug administrations have successively announced the news
that a number of pharmaceutical companies have been suspended and stopped operating for various reasons.
On November 2, the Gansu Provincial Food and Drug Administration issued an announcement
suspending drug business activities.
According to the content of the announcement, Wuwei Pharmaceutical Co.
, Ltd.
, Gansu Min'antang Chain Pharmaceutical Co.
, Ltd.
, and Longxi County Kangda Pharmaceutical Co.
, Ltd.
will suspend drug business from now until April 17, 2023 due to their own reasons, and will not carry out drug business activities during the suspension period, and all sectors of society are requested to supervise
.
Coincidentally, on the same day, the Hunan Provincial Food and Drug Administration issued an announcement
suspending drug business.
According to the content of the announcement, a pharmaceutical company in Hunan applied for suspension due to its own reasons, and the Food and Drug Administration agreed in accordance with the "Notice of the Comprehensive and Planning Finance Department of Hunan Provincial Drug Administration on Further Regulating Issues Related to the Suspension and Resumption of Business of Pharmaceutical Wholesale Enterprises (Retail Chain Headquarters)", and the enterprise was suspended until October 31, 2023, during which the enterprise shall not engage in any pharmaceutical business activities
.
It is worth mentioning that on October 13, the Hunan Provincial Food and Drug Administration just issued an announcement
on the suspension of business of pharmaceutical wholesale enterprises (retail chain headquarters).
According to the announcement, Hunan Jiakang Pharmaceutical Co.
, Ltd.
and Hunan Dewang Pharmaceutical Co.
, Ltd.
have applied to the provincial bureau to suspend business
.
During the period of business suspension, the above-mentioned enterprises shall not engage in any pharmaceutical business activities
.
In addition, the Chongqing Municipal Food and Drug Administration also recently issued an administrative penalty information disclosure form
.
According to the announcement, Chongqing Jinfudao Pharmaceutical Co.
, Ltd.
merged a number of illegal facts from May 2020 to March 2022, and finally the NMPA decided to fine it 500,000 yuan, ordered it to stop production and business for rectification, confiscated the income of the legal representative during the illegal period and imposed a fine
.
In the context of new medical reform and the normalization of centralized procurement, in fact, while the reshuffle of the pharmaceutical market is intensifying, supervision is also becoming stricter
.
Since 2022, the news that a large number of pharmaceutical companies have stopped production, stopped operating, and cancelled certificates and no longer operate have been common in the industry for a long time
.
In addition to suspending production, stopping operations, and canceling certificates, a large number of pharmaceutical companies have been punished
for non-compliant operations since the beginning of this year.
For example, some time ago, an administrative penalty information released by the Yunnan Provincial Drug Administration showed that a pharmaceutical company in Yunnan was punished
for selling counterfeit medicine madder.
In addition, a pharmaceutical company in Wuxi was fined 160,000 yuan and confiscated illegal gains and 20,000 yuan
of illegal property by the Jiangsu Provincial Drug Administration for the production and sale of counterfeit drugs.
In this regard, the industry believes that under the background of the great changes in the pharmaceutical market, the survival challenges of pharmaceutical companies have become more and more large, not only need to face competition between enterprises, but also will face stricter supervision, and the reshuffle of the industry market is inevitable
.
At present, it is approaching the end of the year, and the industry expects that the inspection of the pharmaceutical industry will become more and more intensive
.
For pharmaceutical companies, only by actively making strategic layouts and operating in compliance can they go further
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
